Vimseltinib Approved for Symptomatic Tenosynovial Giant Cell Tumor
Expert Perspectives · Lyn Brook · 2025-02-19
The FDA has approved vimseltinib (Romvimza™, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgery may lead to severe functional limitations or morbidity. This approval marks a significant advancement, providing an effective alternative to surgical intervention for individuals with this progressive disease.
Why This Approval Matters
Tenosynovial giant cell tumor can lead to significant functional impairment and chronic pain, particularly when surgery is not a viable option. With limited pharmacologic treatments available, vimseltinib offers a targeted approach that may preserve mobility and enhance quality of life while reducing the risks associated with surgery.
Breaking Down the MOTION Trial
The approval was based on results from MOTION (NCT05059262), a phase 3, double-blind, placebo-controlled, multicenter study. The trial enrolled 123 adult patients with TGCT for whom surgical resection was not advisable due to potential functional deterioration or severe morbidity. Patients were randomized 2:1 to receive either 30 mg of vimseltinib twice weekly or placebo for a 24-week double-blind period (Part 1). In the open-label extension (Part 2), patients could continue vimseltinib, and those receiving placebo were eligible to switch to active treatment.
Randomization was stratified by tumor location (lower limb versus other) and geographic region (US versus non-US). Patients eligible for the trial had a confirmed TGCT diagnosis with measurable disease per RECIST v1.1, including at least one lesion ≥2 cm.
Efficacy Outcomes
The primary end point was overall response rate (ORR) assessed by blinded independent radiological review at Week 25. The vimseltinib group experienced an ORR of 40% compared to 0% in the placebo group. Durability of response was notable:
- 85% of responders maintained their response for at least 6 months
- 58% of responders maintained their response for at least 9 months
Further, patients receiving vimseltinib exhibited statistically significant improvements in active range of motion, patient-reported physical function, and pain reduction compared to those on placebo.
Managing Adverse Reactions
As with any targeted therapy, vimseltinib is associated with specific side effects that require monitoring. The most common adverse events experienced in ≥20% of those receiving vimseltinib included increased aspartate aminotransferase (AST), periorbital edema, fatigue, rash, increased cholesterol levels, peripheral and facial edema, decreased neutrophils and leukocytes, pruritus, and increased alanine aminotransferase (ALT).
Clinical Implications and Future Perspectives
“Patients treated with vimseltinib experienced statistically significant and clinically meaningful improvements in ORR by RECIST v1.1 and by tumor volume score, active range of motion, physical function, stiffness, health status, and pain versus placebo,” wrote William Tap, MD, an Oncologist at Memorial Sloan Kettering Cancer Center, and colleagues, in their published results of the MOTION study. “Vimseltinib is an effective, well-tolerated colony-stimulating factor 1 receptor (CSF1R)–targeted therapy that demonstrates significant clinical benefit and improves functional health and quality of life in patients with symptomatic TGCT not amenable to surgery.”
Dosing and Administration
The recommended dosage of vimseltinib is 30 mg orally twice weekly, with at least 72 hours between doses.